The 60-second version of Genpharmasec Limited — what it does, how it earns, and who it competes with, before any of the numbers below.
| Metric | FY23 | FY24 | FY25 | FY26 | 3Y CAGR |
|---|---|---|---|---|---|
| Revenue | ₹25 Cr | ₹30 Cr | ₹34 Cr | ₹140 Cr | +76.9% |
| EBITDA | ₹0 Cr | ₹1 Cr | ₹3 Cr | ₹4 Cr | +180.9% |
| EBITDA Margin | 0.8% | 3.7% | 9.9% | 3.1% | — |
| PAT (Net Profit) | ₹1 Cr | -₹0 Cr | ₹2 Cr | ₹2 Cr | +12.6% |
| EPS | ₹0.02 | ₹-0.01 | ₹0.03 | ₹0.03 | +6.4% |
| ROE | 7.3% | -0.3% | 2.4% | 2.4% | — |
| ROCE | 1.9% | 1.0% | 3.8% | 2.3% | — |
| Total Debt | ₹3 Cr | ₹4 Cr | ₹5 Cr | ₹35 Cr | +124.7% |
| Free Cash Flow | -₹3 Cr | -₹3 Cr | -₹3 Cr | -₹18 Cr | — |
| Company | P/E | ROE |
|---|---|---|
| SUN PHARMACEUTICAL IND L | 34.9x | 14.5% |
| DR. REDDY S LABORATORIES | 31.0x | 8.8% |
| CIPLA LTD | 31.8x | 9.8% |
| DIVI S LABORATORIES LTD | 83.0x | 17.5% |
A reasonable business at a reasonable price. Nothing here is alarming and nothing is compelling, which usually means the decision rests on things this data cannot see — the industry's direction, management's intent, and what else is available to you. 4 high-severity red flags sit above this conclusion and should be read first.